Amneal Pharmaceuticals (AMRX) Receives a Buy from Piper Sandler

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $6.76.

According to TipRanks, Amsellem is an analyst with an average return of -2.4% and a 42.57% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Alkermes, Ironwood Pharma, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Amneal Pharmaceuticals is a Strong Buy with an average price target of $8.33, which is a 23.22% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $8.00 price target.

AMRX market cap is currently $2.09B and has a P/E ratio of -11.96.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amneal Pharmaceuticals (AMRX) Company Description:

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.